Related papers: NeuroAPS-Net: Neuro-Anatomically Aware Point Cloud…
Alzheimer's disease (AD) is the most common form of dementia, which causes problems with memory, thinking and behavior. Growing evidence has shown that the brain connectivity network experiences alterations for such a complex disease.…
Alzheimer s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, where early detection is essential for timely intervention and improved patient outcomes. Traditional diagnostic methods are…
Alongside neuroimaging such as MRI scans and PET, Alzheimer's disease (AD) datasets contain valuable tabular data including AD biomarkers and clinical assessments. Existing computer vision approaches struggle to utilize this additional…
Alzheimer's disease (AD) is a heterogeneous, multifactorial neurodegenerative disorder characterized by beta-amyloid, pathologic tau, and neurodegeneration. There are no effective treatments for Alzheimer's disease at a late stage, urging…
In medical image analysis, the subtle visual characteristics of many diseases are challenging to discern, particularly due to the lack of paired data. For example, in mild Alzheimer's Disease (AD), brain tissue atrophy can be difficult to…
Accurate predictions of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) can enable effective personalized therapy. While cognitive tests and clinical data are routinely collected, they lack the predictive power…
The aging population of the U.S. drives the prevalence of Alzheimer's disease. Brookmeyer et al. forecasts approximately 15 million Americans will have either clinical AD or mild cognitive impairment by 2060. In response to this urgent…
Objective: This paper presents an Alzheimer's disease (AD) detection method based on learning structural similarity between Magnetic Resonance Images (MRIs) and representing this similarity as a graph. Methods: We construct the similarity…
Alzheimer's disease (AD) is the most prevalent form of dementia, and its early diagnosis is essential for slowing disease progression. Recent studies on multimodal neuroimaging fusion using MRI and PET have achieved promising results by…
Alzheimer's disease (AD) progresses through distinct stages, from early mild cognitive impairment (EMCI) to late mild cognitive impairment (LMCI) and eventually to AD. Accurate identification of these stages, especially distinguishing LMCI…
In recent years, many papers have reported state-of-the-art performance on Alzheimer's Disease classification with MRI scans from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset using convolutional neural networks. However,…
For precision medicine and personalized treatment, we need to identify predictive markers of disease. We focus on Alzheimer's disease (AD), where magnetic resonance imaging scans provide information about the disease status. By combining…
A major issue in the association of genes to neuroimaging phenotypes is the high dimension of both genetic data and neuroimaging data. In this article, we tackle the latter problem with an eye toward developing solutions that are relevant…
Accurate diagnosis of Alzheimer's Disease (AD) entails clinical evaluation of multiple cognition metrics and biomarkers. Metrics such as the Alzheimer's Disease Assessment Scale - Cognitive test (ADAS-cog) comprise multiple subscores that…
Autism spectrum disorder (ASD) has been associated with structural alterations across cortical and subcortical regions. Quantitative neuroimaging enables large-scale analysis of these neuroanatomical patterns. This project used structural…
Structural magnetic resonance imaging (sMRI) combined with deep learning has achieved remarkable progress in the prediction and diagnosis of Alzheimer's disease (AD). Existing studies have used CNN and transformer to build a well-performing…
Alzheimer's Disease (AD) is a currently incurable neurodegeneartive disease. Accurately detecting AD, especially in the early stage, represents a high research priority. AD is characterized by progressive cognitive impairments that are…
Now that disease-modifying therapies for Alzheimer disease have been approved by regulatory agencies, the early, objective, and accurate clinical diagnosis of AD based on the lowest-cost measurement modalities possible has become an…
A three-dimensional convolutional neural network was developed to classify T1-weighted brain MRI scans as healthy or Alzheimer. The network comprises 3D convolution, pooling, batch normalization, dense ReLU layers, and a sigmoid output.…
The assessment of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) associated with brain changes remains a challenging task. Recent studies have demonstrated that combination of multi-modality imaging techniques can better…